Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Dose-escalationStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALK-N001 for Injection in Patients With Advanced Solid Tumors

NCT07529535 is registered in ClinicalTrials.gov with Zhejiang Anglikang Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07529535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07529535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Dose-escalationStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Lead sponsor
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Suspended
Start date
June 5, 2025
Completion date
December 31, 2026
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advance solid tumors